Latest Technology Platform Development News

Mesoblast has acquired exclusive rights to a patented chimeric antigen receptor platform designed to enhance the targeting and potency of its mesenchymal stromal cell therapies, aiming to expand treatment options for inflammatory and autoimmune diseases.

Axtec Limited maintains a steady cash position through strategic equity placements and cost reductions while advancing its PropTech platform and partnerships.